Amgen Inc.

AMGNleader

Amgen is one of the world's largest biotechnology companies, pioneering the development of biologic medicines since the 1980s. Its acquisition of Horizon Therapeutics strengthened its rare disease portfolio, while MariTide, its obesity drug candidate, represents a potential blockbuster entry into the weight-loss market.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($33.4B)

靜態數據（加載即時財務…）

General Medicine (Prolia, Repatha, Evenity) (35%)

Inflammation (Enbrel, Otezla) (20%)

Oncology/Hematology (25%)

Horizon Therapeutics Portfolio (20%)

業務部門構成與主要客戶

產品詳情

Repatha/Prolia/Xgeva30%

PCSK9 inhibitor for cholesterol and bone-targeting antibodies for osteoporosis/cancer

Enbrel20%

Anti-TNF biologic for rheumatoid arthritis and psoriasis

Tezspire/Lumakras25%

Next-gen asthma biologic and first KRAS inhibitor for lung cancer

供應鏈關係

競爭對手

AbbVie Inc.

Immunology biologics (Enbrel vs Humira)

影響: Long-standing rivalry

Eli Lilly and Company

Obesity and cardiometabolic drugs

影響: Emerging obesity competition

Pfizer Inc.

Biosimilars and inflammation

影響: Broad pharma competition

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 Amgen Inc. 的 AI 供應鏈分析。

企業資訊

總部

Thousand Oaks, California, USA

成立時間

1980

員工人數

27,000+

官網

amgen.com

行業概況 — 제약 / 바이오

行業新聞